ClinVar Miner

Submissions for variant NM_058216.3(RAD51C):c.905-3_906del

dbSNP: rs730881941
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000160935 SCV000211642 pathogenic not provided 2023-10-23 criteria provided, single submitter clinical testing Canonical splice site variant demonstrated to result in complete skipping of exon 7 and predicted to result in a null allele in a gene for which loss of function is a known mechanism of disease (PMID: 35740625); Observed in individuals with breast cancer (PMID: 26681312); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 35740625, 26681312)
Ambry Genetics RCV000570045 SCV000671917 likely pathogenic Hereditary cancer-predisposing syndrome 2023-11-27 criteria provided, single submitter clinical testing The c.905-3_906delCAGGG variant results from a deletion of 5 nucleotides between positions c.905-3 and c.906 and involves the canonical splice acceptor site before coding exon 7 of the RAD51C gene. This variant has been observed in an individual with breast cancer (Susswein LR et al. Genet Med. 2016:18(8):823-32). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). The canonical splice acceptor site is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site. In a functional RNA study, this variant was associated with exon 7 skipping (Sanoguera-Miralles L et al. Cancers (Basel), 2022 Jun;14: Ambry internal data). Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as likely pathogenic.
Labcorp Genetics (formerly Invitae), Labcorp RCV000701513 SCV000830316 pathogenic Fanconi anemia complementation group O 2023-11-28 criteria provided, single submitter clinical testing This variant results in the deletion of exon 7 (c.905-3_906del) of the RAD51C gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in RAD51C are known to be pathogenic (PMID: 20400964, 21990120, 24800917, 29278735). This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with breast cancer (PMID: 26681312). ClinVar contains an entry for this variant (Variation ID: 182846). For these reasons, this variant has been classified as Pathogenic.
Baylor Genetics RCV003462105 SCV004208058 likely pathogenic Breast-ovarian cancer, familial, susceptibility to, 3 2021-06-29 criteria provided, single submitter clinical testing
Myriad Genetics, Inc. RCV003462105 SCV004931482 likely pathogenic Breast-ovarian cancer, familial, susceptibility to, 3 2024-01-03 criteria provided, single submitter clinical testing This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.